Using cytokine adsorption to treat AIDS patients with severe pneumonia or septic shock
Clinical Application of Cytokine Adsorption Technology in AIDS Patients With Severe Pneumonia and/or Septic Shock: An Observational Study.
This study is testing if a new treatment using cytokine adsorption can help AIDS patients with severe pneumonia or septic shock feel better compared to standard treatment alone.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Guangzhou 8th People's Hospital Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06145828 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of cytokine adsorption technology in treating AIDS patients who are suffering from severe pneumonia or septic shock. It involves a single-center, non-randomized cohort design where patients are divided into two groups: one receiving cytokine adsorption combined with standard treatment and the other receiving standard treatment alone. The study will observe and compare the clinical outcomes of these two treatment strategies in real-world settings.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 65 with confirmed HIV infection who have progressed to AIDS and are experiencing severe pneumonia or septic shock.
Not a fit: Patients with severe underlying diseases, central nervous system lesions, or concurrent tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve clinical outcomes for AIDS patients facing severe pneumonia or septic shock.
How similar studies have performed: While cytokine adsorption technology is a novel approach, similar studies have shown promise in treating severe infections, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Confirmed HIV infection; 2. Progression to AIDS stage: CD4+ count \<200 cells/ul and/or occurrence of AIDS opportunistic infections; 3. Age between 18 and 65 years; 4. Meeting the diagnosis of severe pneumonia or septic shock: 1. The criteria for severe pneumonia diagnosis refer to the 2021 ATS (American Thoracic Society) and IDSA (Infectious Diseases Society of America) guidelines for the treatment of community-acquired pneumonia; 2. The criteria for septic shock refer to the Chinese Society of Critical Care Medicine's "Chinese Guidelines for the Emergency Treatment of Sepsis/Septic Shock (2018). Exclusion Criteria: 1. Coexisting central nervous system lesions, severe liver disease, or cirrhosis; 2. Concurrent AIDS-related or unrelated tumors; 3. Women who are pregnant or breastfeeding; 4. Severe underlying diseases of the heart, lungs, liver, kidneys, etc.; 5. Alcohol abuse or drug use; 6. The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial.
Where this trial is running
Guangzhou, Guangdong
- Guangzhou Eighth People's Hospital, Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Linghua Li, PhD
- Email: llheliza@126.com
- Phone: +862083710825
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.